Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
34
COR Quote, Financials, Valuation and Earnings
Last price:
$360.85
Seasonality move
:
2.16%
Day range:
$351.00 - $364.67
52-week range:
$237.71 - $377.54
Dividend yield:
0.64%
P/E ratio:
43.40x
P/S ratio:
0.22x
P/B ratio:
36.78x
Volume:
975K
Avg. volume:
1.3M
1-year change:
47.56%
Market cap:
$70.2B
Revenue:
$321.3B
EPS (TTM):
$8.31
Analysts' Opinion
-
Consensus RatingCencora, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $403.20, Cencora, Inc. has an estimated upside of 11.74% from its current price of $360.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $340.00 representing 5.77% downside risk from its current price of $360.83.
Fair Value
-
According to the consensus of 14 analysts, Cencora, Inc. has 11.74% upside to fair value with a price target of $403.20 per share.
COR vs. S&P 500
-
Over the past 5 trading days, Cencora, Inc. has overperformed the S&P 500 by 2.07% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cencora, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cencora, Inc. has grown year-over-year revenues for 53 quarters straight. In the most recent quarter Cencora, Inc. reported revenues of $85.9B.
Earnings Growth
-
Cencora, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cencora, Inc. reported earnings per share of $2.87.
Enterprise value:
76.5B
EV / Invested capital:
7.64x
Price / LTM sales:
0.22x
EV / EBIT:
20.22x
EV / Revenue:
0.23x
PEG ratio (5yr expected):
2.37x
EV / Free cash flow:
21.21x
Price / Operating cash flow:
19.49x
Enterprise value / EBITDA:
15.86x
Gross Profit (TTM):
$10.6B
Return On Assets:
2.22%
Net Income Margin (TTM):
0.5%
Return On Equity:
107.99%
Return On Invested Capital:
16.71%
Operating Margin:
1.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $271.6B | $303.2B | $325.8B | $81.5B | $85.9B | |
| Gross Profit | $8B | $8.8B | $10.6B | $2.3B | $2.7B | |
| Operating Income | $2.6B | $3B | $3.8B | $791.8M | $926.7M | |
| EBITDA | $3.6B | $4.2B | $4.8B | $1.1B | $1.2B | |
| Diluted EPS | $9.18 | $7.03 | $8.31 | $2.50 | $2.87 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.4B | $40.7B | $44.9B | $50B | $54.2B | |
| Total Assets | $57.6B | $57.9B | $64.7B | $69.1B | $78.4B | |
| Current Liabilities | $41.6B | $44.8B | $50.8B | $54.5B | $59.1B | |
| Total Liabilities | $57B | $57.8B | $63.6B | $68.7B | $76.3B | |
| Total Equity | $601.1M | $73.6M | $1.1B | $361.9M | $2.1B | |
| Total Debt | $6.7B | $5.6B | $4.8B | $8.1B | $7.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $4.1B | -$119.3M | $4.3B | -$2.7B | -$2.3B | |
| Cash From Investing | -$1.2B | -$895.3M | -$4.9B | -$343M | -$299.3M | |
| Cash From Financing | -$1.8B | $1.4B | -$916.8M | $3.2B | $43.2M | |
| Free Cash Flow | $3.6B | -$638.1M | $3.6B | -$2.8B | -$2.4B | |
COR
Sector
Market Cap
$70.2B
$24M
Price % of 52-Week High
95.57%
48.29%
Dividend Yield
0.64%
0%
Shareholder Yield
-0%
-1.62%
1-Year Price Total Return
47.56%
-22.92%
Beta (5-Year)
0.676
0.500
Dividend yield:
0.64%
Annualized payout:
$2.20
Payout ratio:
20.94%
Growth streak:
20 years
Technicals
8-day SMA
Buy
Level
$355.28
200-day SMA
Buy
Level
$316.99
Bollinger Bands (100)
Buy
Level
323.41 - 360.39
Chaikin Money Flow
Sell
Level
-2.3M
20-day SMA
Buy
Level
$355.21
Relative Strength Index (RSI14)
Buy
Level
54.24
ADX Line
Sell
Level
21.21
Williams %R
Neutral
Level
-29.9915
50-day SMA
Buy
Level
$347.01
MACD (12, 26)
Buy
Level
94.15
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
3.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.8706)
Sell
CA Score
(Annual)
Level (-0.7035)
Buy
Beneish M-Score
(Annual)
Level (-2.5377)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.8039)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.
Stock Forecast FAQ
In the current month, COR has received 11 Buy ratings 3 Hold ratings, and 0 Sell ratings. The COR average analyst price target in the past 3 months is $403.20.
-
Where Will Cencora, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cencora, Inc. share price will rise to $403.20 per share over the next 12 months.
-
What Do Analysts Say About Cencora, Inc.?
Analysts are divided on their view about Cencora, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cencora, Inc. is a Sell and believe this share price will drop from its current level to $340.00.
-
What Is Cencora, Inc.'s Price Target?
The price target for Cencora, Inc. over the next 1-year time period is forecast to be $403.20 according to 14 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is COR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cencora, Inc. is a Buy. 11 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COR?
You can purchase shares of Cencora, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cencora, Inc. shares.
-
What Is The Cencora, Inc. Share Price Today?
Cencora, Inc. was last trading at $360.85 per share. This represents the most recent stock quote for Cencora, Inc.. Yesterday, Cencora, Inc. closed at $360.83 per share.
-
How To Buy Cencora, Inc. Stock Online?
In order to purchase Cencora, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get COR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
COR
Sector
P/E ratio
43.40x
23.44x
PEG ratio
2.37x
-0.01x
P/B ratio
36.78x
1.73x
Price / LTM sales
0.22x
1.51x
Growth Metrics
COR
Sector
Revenue growth
5.46%
3.31%
Earnings growth
14.47%
10.7%
Revenue (5-year growth)
11.09%
6.28%
Earnings forecast
$4.04
-$0.19
Profitability
COR
Sector
Profitability FY 2025
$10.1B
$2.6M
Return on invested capital
16.71%
-33.62%
Return on assets
2.22%
-29.74%
Return on equity
107.99%
-39.33%
Earnings Date
Last Earnings Date
Feb
4
Next Earnings Date
May
6
Estimated Next Earnings Date
May
6
Balance Sheet
COR
Sector
Total cash
$1.8B
$25M
Short term investments
--
$23.9M
Total assets
$76.6B
$71.9M
Long term debt
$7.9B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
